Is Now On Sale! You can Buy Cheap & Low Prices on
Discount. Read More Reviews. ...
Since the DSM-IV ® was published in 1994, we saw many advances in our understanding of mental disorders. This text contains information for review of a comprehensive review of research on mental disorders published since DSM-IV ® was completed in 1994 slaughtered. Current information on the functions associated, culture, age and gender characteristics, prevalence, course and familial pattern of mental disorders included. DSM-IV ® brings this essential diagnostic tool in the
Listprice :$ 115.00
The health sector in India is growing at a rapid pace and is ready to become one of the dominant participants in the Indian economy. A report by the Bank and Yes ASSOCHAM, the Indian Health is estimated to grow at 23% per year for the current 77000000000-2012 $ 35,000,000,000 th sector grew at a rate of 9.3% from 2000 to 2009 . The sum would be diagnostic and pathology in 2012 for $ 2.5 billion bill, more than double the current size estimated $ 1 billion. Growth in the segment should be driven by industry consolidation and increasing insurance penetration among the population. Health facilities, including public and private hospitals, the central area, is located in health centers, continue to contribute 70% of the entire sector and reach a value of $ 54700000000-2012 According to the McKinsey report The Indian healthcare market is expected with a rate of 10-12 percent per year This growth was driven by strong local demand and the growing population. An increasing average household consumption is expected to more than 7 percent per year, the annual cost of health care to increase by 10 percent and the number of policyholders are likely to jump from 100 to 220 million. The high population density of India makes it an important player in this industry. According to the Insurance Regulatory Authority and Development, the Indian pharmaceutical industry has the opportunity to have the same exponential growth that the software and pharmaceutical industries shown in the last ten years to show. Only 10 percent of the potential market opened today. This is indicative of the potential for strong growth of Indian healthcare market. Recent years have seen an increase in the purchasing power of the middle class. With a sedentary lifestyle and sudden urban middle class growing middle and upper India, has become an important part in the health of all life. Health spending is rising with increased self-awareness and availability of quality health care facilities with the advent of private players. According to ICRA 2005 Report on the Indian healthcare industry, India spends 5.10 percent of GDP on health care. Spending on health in India as a percentage of GDP is among the highest in developing countries. India is seen as the preferred destination for quality medical solutions because of the significant cost advantage compared to Western countries. The diagnosis and pathology tests in India is one of the most lucrative markets in the world. The market has grown strong in recent years on the back of the increasing prevalence of the disease and the growing awareness of consumers. There are two major segments of the diagnostic market: 1) Pathological Laboratories 2) diagnostic kits and reagents The above two segments offer great potential for growth, both domestic market and as a preferred hub for clinical trials and outsourcing from Western countries. Revenue from diagnostic segments expected to grow at an annual growth rate of nearly 20% during the period 2010-2012. With the awareness of people about it, a healthy lifestyle, the diagnostic market in India is a growth in the coming years of experience. The country is currently experiencing strong growth in biochemical and molecular diagnostics segments. The pathology market is currently around 2.5 percent of the total market for health care. According to industry estimates there are over 40,000 independent pathology service across the country 1-1250000 patients a day. This includes specialized laboratories, laboratories in hospitals and nursing homes and small laboratories with basic equipment. The quality of services provided by these laboratories is very different. The National Council for Accreditation of Laboratories (NABL) was established to accredit laboratories, but the number of accredited laboratories is indeed still a majority of the players, the minimum in the large informal sector. Are Currently, there are few large national players such as Super Religare Laboratories, Dr. Lal Pathlabs, Metropolis, Thyrocare, Max Healthcare and Apollo Hospitals. Quest Diagnostics has joined an important international player and India in recent years. The industry is highly competitive and price-driven with bribes and business transfer payments in the absence of a regulatory body. About 70 percent of treatment decisions in the country are based on laboratory results. Super Religare Laboratories Dr Lal Pathlabs Metropolis Thyrocare Labs and personal Quest Diagnostics diagnostic kits and reagents segment in India is a relatively new segment. Diagnostic kits include syringes, Vacutainer, buffers, etc. used at the time of sampling, reagents, while compounds such as sulfuric acid, hydrochloric acid, caustic soda, etc., used in the laboratory of chemical analysis or experiments. In addition to the presence of international players, India currently has more than 25 companies manufacturing diagnostic kits. These companies manufacture and sale of diagnostic kits, particularly in the areas of pregnancy, ovulation, estimation of T3, T4 and TSH, HIV, HBV and HCV, rheumatic diseases and disorders, the cancer (cervix, colon, prostate, lung -., mouth, etc.), kidney and liver. There was an increase in the use of diagnostic equipment and tests in recent years. The main reason is the increase in consumer awareness, rising consumer incomes of the middle and pushed into the health insurance that will lead to increased use of diagnostic kits. The number of tests over the past decade, more than 180 million to over 500 million doubled. There are over 11,500 hospitals and 14,000 diagnostic laboratories in the country, to use large quantities of diagnosis. The main factor is the growth in production of diagnostic kits in India, the advantage of 70-80 percent of the costs that Indian laboratories offer their Western counterparts. The Indian company with R & D institutions have a number of high quality products that give stiff competition to imported kits developed. However, there are hi-tech products such as ELISA, PCR, some cancer markers and other products for which there are very few manufacturers in the country. Although there have been significant developments, but the diagnostic kits and reagents market has come a long way to go. include some of the companies manufacturing diagnostic kits Accurex Biomedicals, Beacon Diagnostics, Bhat Biotech and Bio-diagnostic systems J Mitra & Co, Monozyme India, Span Diagnostics Ltd, Transasia Biomedicals, Tulip Group XCyton and diagnostics. Recently, the pathological diagnosis of Indian Industry and is currently an action with the entry of big players and international companies. In addition to growth in the domestic segment, India has the potential to become an international hub for clinical trials and export of reagents and diagnostics. The cost advantage that Indian companies may have more than their Western counterparts play a key differentiator. Some trends in the segment of Indian pathology know: Today, there are 800 private laboratories in the United States, including the top 10 laboratories perform 85 percent of the load pathological work. Earlier in India, the United States also had an independent laboratory, but the scenario changed when the health insurance market in the U.S. health care. Insurance companies with quality control laboratories had standardized systems for billing and related services. This consolidation came and changed the operation. As in India, the public health system is collapsing and there is a growth of about 20 percent in the private sector each year. International Travel Health India to bind to the pathology of the chains, resulting in the face of the diagnostic industry. With the advent of the great chain of pathology laboratories, diagnostic crossed the Indian countryside some significant changes in the last four minutes five years ago. One of the most important effects will be increased competition among the major players who have not for the price to consumers may have been cut, but certainly the entry barriers for laboratories modestly, lifted in the nineties for fungi uncontrollable proportions. Well, we say great way laboratories located before the combination, and they cite the example of the United States, which develops in a similar way, but now only four major chains dominate laboratories path. Although major road were laboratories shows impressive growth rates (for example, claims that his company Metropolis has increased by 50 percent over the previous year, while the overall market was estimated to grow 25 per cent), much of the market still dominates the sector. large laboratories have surpassed the estimates of industry growth and obviously they eat in the share of small laboratories. For example, a test for diabetes is usually in small laboratories by calculating arbitrary 80-90 percent of cases is conducted. Large laboratories suggest that this method is not reliable, while providing accurate results direct estimate. Since the rise of consumer awareness, the players are organized with greater emphasis on quality and accuracy for smaller players, the front. With the advent of international players and large companies, there was an emphasis on providing a better quality of transport of samples collection, the real test of the sample in the laboratory. It
a significant improvement in the sampling process with the use of sealed sample collection kit, and was Vacutainer. It was a strong emphasis on training phlebotomists (technicians, blood collection), the emphasis on technical skills and communication to improve end user experience
Another highlight is the use of codes bar to track samples. and adequate transportation for delivery of the sample to the laboratory and the avoidance of the sample was misalignment. Finally, temperature-controlled gel packs and boxes to keep getting used to the integrity of the sample, while maintaining accurate reports. Wellness Test is a new concept and has been for people in good health who are not aware that they will suffer from certain diseases. Among the players organized, there has been a growing trend toward targeting healthy people who are sedentary are more likely prone to lifestyle diseases such as cardiovascular disease and diabetes. Organise the players have developed particular panel panels screening the whole body, Control of diabetes, cardiovascular panel, thyroid panel, etc., in order to tap into this segment. A panel consists of bunch of tests for this specific disease or infirmity. For example, a thyroid panel should be composed of specific tests such as T3, T4 and TSH. Therefore, these plates for packaging the final product are designed and easy to understand and thorough study, compared to individual tests. The idea is to introduce consumers to help themselves, these tests, rather than a doctor's prescription, usually for testing more advanced and complex diseases such as cancer, osteoporosis and others is needed. Promoting
Thus, companies are trying to create an interest in the diagnostic category among the masses so that they can monitor their blood disease itself and generates a lot of consumer engagement.
Recently a lot of action is seen in billboards by major players diagnostic and hospitals. This is a conscious effort by the major players, their brands and services of competitors and the informal sector have been different. On Apollo Hospitals SRL, Fortis, Dr Lal Pathlabs, everyone was more focused on advertising and to the development of the brand, the absence of 3-4 years. companies are looking for specific tests in terms of signs of health and illness, to create a rule and a bunch of tests to check the overall health or specific diseases. To promote these products above the line (ATL) and below the line (BTL), the media for the same purpose. Out of print, radio everywhere on direct marketing, diagnosis and Pathlabs. kits and reagents segment offers a great opportunity. But there are still several issues that is to act as barriers and a strong effect of the industry and the government needs to facilitate the same. Some key features are: Although there are great opportunities in diagnostic kits and production segment of the reagents, but more than half of imported kits. These kits are imported at a higher cost and are often ineffective because it is not designed for Indian climatic conditions. This is a great opportunity in the production of substitutes for these imported kits and reagents according to Indian demands. But there are some obstacles in the way they are identified as follows: high import duties on raw materials and clearance procedures, competition from Western companies that offer more sophisticated products, lack of knowledge and expertise among Indian producers, Licenses and slow approvals of regulatory authorities, lack of network of national laboratories for evaluation and approval of new products are just some of the factors slowing the pace of naturalization.
Red-tapism, lack of power will be strong, the company remains the diagnosis, the regulatory confusion and less room for some of the issues with which the growth of the segment. In addition, the segment is very small, it is difficult to control. Imports of raw materials to high costs is an important issue before the segment.
There is an urgent need to address these issues with government authorities at. It
a serious chance in the diagnostic kits and reagents business, but our contractor is on this lucrative sector are missing. While the opportunity is huge, there are some obstacles in their way. These are as follows:.
Lack of knowledge about the range of products, lack of technical know-how for these medical kits and reagents, the complex nature of the manufacturing process
in India there is still a gap between the industry and academia. The authorities need to work to improve public-private partnership. This will result in the proper use of public funds and technology transfer to the private sector.
The Department of Biotechnology (DBT) was developed to facilitate the transfer of many technologies for diagnostic kits for the industry in the laboratories of CSIR. There are no uniform guidelines and procedures for granting licenses for the manufacture of diagnostic products. The licensing of product areas lack both for products manufactured in India or imported products. These vary from state to state. There is no special exemption from taxes and parcel of the government for diagnostic methods factories. The number of technology transfers cheaper and more effective in the field of diagnostics is limited. The industry is seen as part of its Pharmaceuticals segment, but not really be there. The authorities themselves are not well informed about the diagnostic industry. Current rate of duty is a great encouragement, production is not profitable. Also there is a lack of any commercial organization of diagnostic kits and reagents for the manufacturer of these important issues with the authorities. India has the potential of the global platform for R & D, clinical and pathology. The main reasons are to support awareness of the health and quality awareness in the growing middle class, opening the insurance sector, the emergence of private actors and consolidations in the diagnosis and segments of pathology considerable cost advantage of the availability of the segment of clinical trials of medical professionals, increased testing requirements in urban and rural areas and the introduction of public-private partnerships. But some corrective action before the industry and government on various issues such as licensing, competition, limited technical expertise and a high proportion of imported goods required address. Industry Report IBEF Health, National Accreditation Board for testing laboratories and calibration; BioSpectrum india indian Expres Healthcare Management India PR Wire Factory Original OEM shop manuals for Ford Gm and Chrysler 1909-1981, Auto Repair Books download instantly, Car diagnostic and troubleshooting Maintenance guides and eBooks for Musclecars, Classic, antique and Vintage Cars & trucks Earn 30% on every sale!
Auto Repair Manuals Download PDF eBooks 400 Titles
Diagnostic
